Slide 1: Investor Webinar Presentation (ASX release)
ASX: EIQ RELEASE 7 March 2025 Investor Webinar Presentation Sydney: AI and Medical Technology company Echo IQ (“the Company” or “Echo IQ”) (ASX: EIQ) is pleased to provide the attached presentation, which will be used during the Company’s upcoming webinar scheduled for 11:00am AEDT on Thursday, 13 M
Slide 2: Webinar Presentation March 2025
Webinar Presentation March 2025 ASX: EIQ OTC: ECHQ.F
Slide 3: Andrew Grover and Dustin Haines
Andrew Grover Dustin Haines Executive Chairman Chief Executive Officer Mr Grover brings 25 years’ experience in Mr Haines brings 25 years’ experience in growing successful businesses across a leading global businesses in pharmaceuticals, diverse range of industries. As a founder and biotechnology, a
Slide 4: Board of Directors
Board of Directors Steven Formica Steve Picton Ken Nelson Jessamyn Lyons Board Member Board Member Board Member Company Secretary Steven Formica brings to the company Steve Picton is an experienced Board Ken Nelson is a leading US-based medical Jessamyn Lyons is a Chartered Secretary, a significant
Slide 5: Management team
Management team Deon Strydom Sam Dribin Don Fowler Dane Brescacin Chief Operating Officer Chief Technology Officer President, Echo IQ US VP Regulatory Affairs Deon Strydom is an experienced Sam Dribin’s specialties include Leveraging experiences as a CEO, Dane Brescacin brings 15 years of executive
Slide 6: Specialist Advisors & Scientific Advisory Board
Specialist Advisors & Scientific Advisory Board Echo IQ has unparalleled scientific backing: Specialist Advisors and Technology Developers: Globally recognized experts in cardiovascular medicine, echocardiography, sonography, and applied AI Excellent public health expertise to assist with commer
Slide 7: Corporate Overview
Corporate Overview Corporate Snapshot: Shares on issue: 585.5m ASX code: EIQ OTC code: ECHQ.F Shareholder breakdown: Share price: A$0.27 As 7 March 2025 Market capitalization: A$156m As at 0.27 per share Cash at bank: A$5.35m 47% As 31 December 2024 53% R&D Tax Incentive: $1.26m Received on 12 Febru
Slide 8: A Defined Mission
A Defined Mission To help more people get matched with the right life-saving treatments for cardiovascular disease, which remains the world’s leading cause of death. 2m Help 2m people into the right care by 2030 7
Slide 9: Investment Summary
Investment Summary Strong investment thesis and multiple pending value catalysts: • Large TAM in US for • Exclusive rights to Aortic Stenosis and worlds largest Aortic stenosis solution cleared by FDA with defined pathway for EchoSolv Heart Failure longitudinal patient outcomes database HF to gain
Slide 10: What we do
What we do harnesses the power of artificial intelligence and exclusive access to world leading cardiac big data to help healthcare professionals obtain earlier and more accurate diagnosis of structural heart disease 9
Slide 11: Tackling Healthcare's Biggest Problem
Tackling Healthcare’s Biggest Problem Diseases of the heart are the leading cause of death worldwide While treatment options are improving, accurate diagnosis remains complex Delayed or missed diagnoses cost lives and impact healthcare systems $250Bn⁴ 33 sec⁵ 50%⁶ US health expenditure on One person
Slide 12: Technology Benefits
Technology Benefits Improved diagnostic accuracy 98.6% vs human only diagnosis 58 - 83%* 20+% reduction in echo reading time Realtime diagnosis - results available in under 3 seconds Consistent diagnosis regardless of age, sex or race Earlier detection of disease Increased valve referral
Slide 13: Total Addressable Market in the US
Total Addressable Market in the US Heart Failure: ~10m echocardiograms per year $10Bn⁷ $70Bn⁹ Reimbursement of US$200 to US$300 for HF diagnosis Healthcare expenditure Healthcare expenditure 6.7m sufferers with 1.2m new diagnoses per year for Aortic Valve disease for heart failure Only 50% o
Slide 14: EchoSolv: Rapid Development and Testing
EchoSolv: Rapid Development and Testing Following algorithm development in 2021, Echo IQ has considerably advanced validation, regulatory, and reimbursement initiatives in EchoSolv for Aortic Stenosis and Heart Failure Aortic Stenosis: Clinical Studies Application Reader Study FDA Clearance Deployme
Slide 15: EchoSolv: Clinical Evidence
EchoSolv: Clinical Evidence International Cohort Studyⁿ (Harvard Medical School) (Published: JASE) Study Size: Study Size: Study Size: Study Size: 31,141 8,257 248,646 (US and Australia) 200,000 Key Findings: Key Findings: Key Findings: Key Findings: 1. EchoSolv identified 100% of the 1. EchoSolv id
Slide 16: Significant Progress in the Last 60 Days
Significant Progress in the Last 60 Days Expanding our Brand Strengthening the Team • OTCQB process Protecting the started Business • New CTO in place in the US • Investor and large Reimbursement conference • International • Consultants for attendance Partnering patent review completed reimbursement
Slide 17: US Reimbursement Strategy
USUS reimbursement Pathway Reimbursement on Track Strategy on Track 1 2 3 Miscellaneous Code Category III CPT Code Category I CPT Code Filled with CMS in Feb 2025 Increased usage in market Code – 93799 Societies and KOL required Coverage – Medicare endorsement for Societies and KOL submissio
Slide 18: Subscription Model with Reimbursement for Aortic Stenosis
Subscription Model with Reimbursement for Aortic Stenosis Graduated model based on reimbursement approval rates Avg Avg Avg Miscellaneous Code Category III Code Category I Code approval approval approval 20-40% 40-60% 80-100% Model for demonstration: Annual Subscription Agreement Fee = (# of Echocar
Slide 19: EchoSolv AS: Commercialization Underway
EchoSolv AS: Commercialization Underway Overview: 510(k) clearance awarded by the US FDA in October 2024 Flagship integration secured with Harvard’s Beth Israel Deaconess Medical Center, Boston USA Miscellaneous reimbursement code identified for users – providing US$100-US$150 in reimbursement
Slide 20: EchoSolv AS: Flagship Integration
EchoSolv AS: Flagship Integration Flagship deployment in Boston underpins strategy to validate technology in partnership with major hospital networks: Beth Israel Deaconess Medical Center (BIDMC or Beth Israel) is a leading US healthcare facility and part of Harvard Medical School BIDMC has 743
Slide 21: 2025 Commercial Pathway
2025 Commercial Pathway Three critical stages to accelerate revenue growth into 2026 Hospital Integrations 3-month free trial for all Revenue customers 4-month sales cycle from Heart Failure Clearance integration to revenue 3 distinct approaches: Estimated Q4 25/Q1 26 for -Individual hospital system
Slide 22: Heart Failure: A Significantly Larger Issue
Heart Failure: A Significantly Larger Issue 6.5m Americans over 20 have heart failure with another 1.2m new cases found per annum Heart failure is the leading cause of re-hospitalization in the US Heart failure accounts for 17% of all US healthcare expenditure and is a US$70Bn annual market Current
Slide 23: EchoSolv HF Results Presented at ESC Congress 2024
EchoSolv HF Results Presented as Late Breaking Science at European Society of Cardiology (ESC) Congress 2024 22
Slide 24: EchoSolv HF: A Solution for a Major Condition
EchoSolv HF: A Solution for a Major Condition Study Outputs: 50% of patients in this cohort were misdiagnosed or underdiagnosed AI alone detected 86% of patients with HF AI with Cardiologist review detected 97% Total high risk of patients with HF cases identified CLINICAL using solution PRACTICE
Slide 25: EchoSolv HF: Defined Regulatory Pathway
EchoSolv HF: Defined Regulatory Pathway Clinical Studies (A) FDA pre-sub Clinical Studies (B) FDA 510(k) application FDA clearance Proof of concept Validate study design Validation with US Using EchoSolv AF as Allowing for immediate Australian-based meeting this quarter partner in country – predicti
Slide 26: Clinical Pipeline
Clinical Pipeline Other Structural Pulmonary Heart Hypertension Diseases Development stage Heart Failure First pilot study estimated Q4 25 FDA submission Q1 25 Aortic Stenosis FDA 510K cleared Oct 24 2024 2026 2028 25
Slide 27: Scalable Business Licensing Opportunities
Scalable Business Licensing Opportunities Integration Identify additional patients that Integrate EchoSolv solution would benefit from a valve Rapid deployment with into hospital workflow and Device Manufacturers hospitals, clinics, and intervention or alternative continue to educate users partners
Slide 28: Contact: Mr Dustin Haines Chief Executive Officer
Contact: Mr Dustin Haines Chief Executive Officer Dustin.haines@echoiq.ai +1 (919) 624 5212 Henry Jordan Six Degrees Investor Relations Henry.jordan@sdir.com.au +61 (0) 431 271 538
Slide 29: Disclaimer and Forward-looking Statements
Disclaimer and Forward-looking Statements This presentation has been prepared by ECHOIQ LIMITED “EIQ”. This document To the fullest extent permitted by law, EIQ, its officers, employees, agents and contains background information about EIQ current at the date of this advisors do not make any represe